Diagnoptics News

What is new?

Read all news items about the AGE Reader, Diab-spot and DiagnOptics.

Diagnoptics appoints SMT Medical as new distributor in Germany

Groningen, the Netherlands – January 15, 2018.

Diagnoptics announces SMT Medical technology GmbH&Co. KG (SMT Medical) has been appointed as the second distributor of the AGE Reader mu in Germany. 

Diagnoptics appointed SMT Medical as the co-exclusive distribution partner next to earlier appointed MSP Bodmann GmbH (Endocrinology, Diabetology, Pharmacy, General Practitioners). SMT will be serving the following markets as an exclusive distributor:

  • Angiology & Phlebology Neurology & Neurosurgery
  • Corporate Health & Wellness Epidemiology
  • Preventive and Anti-Aging Medicine Cardiology & Hypertensiology
  • Nephrology & pediatric nephrology

“Diagnoptics was seeking an additional distribution partner in these areas after receiving a lot of interest in the last year. Diagnoptics has been building a sound basis in the German market for some time and now the time was right to start a collaboration with a local and experienced distribution partner. We are very glad that with SMT, as our long-term valued partner, we have been able to appoint an experienced team to help explore the German market for the new AGE Reader mu connect.” said Diagnoptics’ CEO Bart van den Berg.

For more than ten years, the team of SMT medical has been collaborating with Diagnoptics in the distribution within the German speaking countries. With the AGE Reader SU activities were mostly limited to the research area. Rolf Schlegelmilch, managing director of SMT: “We are very enthusiastic about the closure of a new distribution agreement with Diagnoptics for the successor model AGE Reader mu. In contrast to the previous model, the technically advanced and substantially less expensive AGE Reader mu offers a high potential for the sale in the private practice office and the specialized hospital department. Especially the application in a broad patient population and the favorable reimbursement with short amortizations are attractive benefits for the doctor’s office. Also the usage of the instrument in the well-publicized areas of preventive medicine as well as public and corporate health programs offer excellent sales opportunities. We look forward to a continued cooperation with Diagnoptics in expanding sales and enhancing success of the AGE Reader MU in D-A-CH.”

Share this link on:

Latest news items

  1. Diagnoptics appoints SMT Medical as new distributor in Germany 15 January 2018
  2. Breakthrough publication: diabetes screening with AGE Reader 24 November 2017
  3. AGE Reader product updates at EASD 2017 – Lisbon 13 September 2017
  4. MSP bodmann GmbH appointed as new distributor in Germany 29 June 2017
  5. New key publication: large scale study in metabolic syndrome 13 June 2017
  6. Diagnoptics appoints DiosPharma as the new Korean distributor 7 November 2016
  7. Visit Diagnoptics at the EASD congress 2016 in Munich 26 August 2016
  8. Selista appointed as new Japanese distributor for the AGE Reader mu 19 May 2016
  9. Diagnoptics bei dem DDG Kongress in Berlin 16 April 2016
  10. Diagnoptics receives Chinese market approval for AGE Reader SU 12 February 2016
More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
Age Reader MU
The AGE Reader mu is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced pricelevel. The AGE Reader mu is a perfect tool for diabetologists and family doctors. Read more »
Newsletter subscription

If you want to receive the newsletter with information about DiagnOptics' products, please send us your email address.

About the company

Find information about Diagnoptics.

Information for patients

Find information about Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Find information about Advanced Glycation Endproducts, the AGE measurement and the clinical validation.a